SCHEMBL20119563

SCHEMBL20119563

Fc1c[nH]c2nc(Cl)nc(NCc3nccs3)c12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TRPM5 Q9NZQ8 1/20 0.35
KDM1A O60341 1/20 0.34
MAOB P27338 1/20 0.34
PTK2 Q05397 3/20 0.34
MAP3K8 P41279 1/20 0.33
TLR7 Q9NYK1 1/20 0.33
DYRK1A Q13627 4/20 0.32
DYRK1B Q9Y463 4/20 0.32
DYRK2 Q92630 3/20 0.32
CLK1 P49759 3/20 0.32
ADORA3 P0DMS8 1/20 0.32
ALDH1A1 P00352 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CLK2 P49760 2/20 0.32
CLK4 Q9HAZ1 2/20 0.32
DYRK3 O43781 1/20 0.32
DYRK4 Q9NR20 1/20 0.32
IGF1R P08069 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119881 0.89 HRH4 (0.37) HRH4SMN1; SMN2TRPM5KDM1AMAOB
SCHEMBL20119647 0.86 HRH4 (0.38) HRH4SMN1; SMN2TRPM5KDM1AMAOB
SCHEMBL20119976 0.83 CHUK (0.45) HRH4SMN1; SMN2MAP3K8
SCHEMBL22358603 0.78 HRH4 (0.33) HRH4TRPM5MAP3K8TLR7DYRK1A
SCHEMBL20119582 0.77 SMN1; SMN2 (0.42) HRH4SMN1; SMN2TRPM5KDM1AMAOB
SCHEMBL20119691 0.76 HRH4 (0.43) HRH4SMN1; SMN2TRPM5KDM1AMAOB
SCHEMBL20119362 0.75 PDE5A (0.40) ALDH1A1ESR1
SCHEMBL20119892 0.74 KCNH3 (0.43) SMN1; SMN2PTK2MAP3K8DYRK1ADYRK1B
SCHEMBL24390684 0.74 HRH4 (0.33) HRH4TLR7ESR1
SCHEMBL29238781 0.74 HRH4 (0.33) HRH4TLR7ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885SMN1; SMN2 11/4885TRPM5 4390/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885SMN1; SMN2 11/4885TRPM5 4390/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885SMN1; SMN2 11/4885TRPM5 4390/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885SMN1; SMN2 11/4885TRPM5 4390/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885SMN1; SMN2 11/4885TRPM5 4390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.